These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 3236408)
1. [Treatment of multiple myeloma: renal function in relation to its prognosis]. Akashi M; Ohta M; Kitagawa S; Furukawa Y; Takeda K; Muroi K; Komatsu N; Ikeda K; Ohsaka A; Yoshida M Rinsho Ketsueki; 1988 Nov; 29(11):1991-7. PubMed ID: 3236408 [No Abstract] [Full Text] [Related]
2. [Comparative studies of intermittent melphalan and prednisolone (MP) versus 5-drug regimen (QUVMP) and 3-drug regimen (QUP) in multiple myeloma]. Hoshino S; Saito H; Wada M; Akutsu M; Shiozaki H; Takanashi M; Takei Y; Tanaka S; Teramura M; Takada K Rinsho Ketsueki; 1987 Mar; 28(3):358-65. PubMed ID: 3475485 [No Abstract] [Full Text] [Related]
3. [Combination chemotherapy with melphalan, cyclophosphamide, vincristine, ACNU and prednisolone (MEV(Ac)P) for multiple myeloma]. Takagi T; Oguro M; Sakai C Rinsho Ketsueki; 1986 Dec; 27(12):2249-53. PubMed ID: 3471977 [No Abstract] [Full Text] [Related]
4. [Polychemotherapy versus melphalan-prednisone in multiple myeloma]. Leoni P; Salvi A; Brianzoni MF; Centurioni R; Montillo M; Olivieri A G Clin Med; 1986 Dec; 67(5-6):291-6. PubMed ID: 3609590 [No Abstract] [Full Text] [Related]
5. [Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)]. Montalbán C; Sevilla F; Zapatero A; Blanco L; Sabán J; Serrano M; Serrano Ríos M Rev Clin Esp; 1985 May; 176(8):392-5. PubMed ID: 3839590 [No Abstract] [Full Text] [Related]
6. [Multiple myeloma: therapeutic response to 2 modalities of chemotherapy]. Lira P; Walker B; Grebe G Rev Med Chil; 1986 May; 114(5):436-40. PubMed ID: 3589221 [No Abstract] [Full Text] [Related]
7. Clinical experience of K18 (IgG-melphalan) for five cases of refractory multiple myeloma. Kanamaru R; Wakui A; Ishioka C; Okuno M; Konishi Y; Ishikawa A; Shibata H Sci Rep Res Inst Tohoku Univ Med; 1988 Dec; 35(1-4):35-40. PubMed ID: 3267125 [No Abstract] [Full Text] [Related]
8. Factors associated with recovery of renal function in patients with multiple myeloma who were treated with hemodialysis. Katagiri D; Hagiwara S; Minami E; Katsuma A; Masumoto S; Hoshino T; Inoue T; Shibata M; Tada M; Nakamura T; Shimbo T; Hinoshita F Nephron Clin Pract; 2011; 117(1):c28-32. PubMed ID: 20689322 [TBL] [Abstract][Full Text] [Related]
9. [Rheumatoid arthritis and multiple myeloma--the risk of a combination of the 2 diseases]. Lila AM; Mazurov VI; Novik AA Ter Arkh; 1997; 69(2):50-2. PubMed ID: 9173578 [No Abstract] [Full Text] [Related]
10. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039 [TBL] [Abstract][Full Text] [Related]
11. [Results of polychemotherapy (a VMCP/VCAP program) in multiple myeloma]. Wutke K; Anger G Z Gesamte Inn Med; 1983 Dec; 38(23):630-3. PubMed ID: 6689459 [TBL] [Abstract][Full Text] [Related]
12. [Immunological and rheological disorders in multiple myeloma patients]. Abdulkadyrov KM; Bessmel'tsev SS; Liubimova NIu Ter Arkh; 1991; 63(7):122-6. PubMed ID: 1788790 [TBL] [Abstract][Full Text] [Related]
13. [Combination chemotherapy of MCNU, melphalan, procarbazine, and prednisolone (MMPP) in multiple myeloma; disappearance of M-peak on serum electrophoretic pattern]. Kamiya O; Hoshino A; Ohara K; Nagata K; Ono Y; Saito M; Itou T; Yamamoto K Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 1):863-5. PubMed ID: 2469398 [No Abstract] [Full Text] [Related]
14. Satisfactory remission in a case of IgD myeloma: effectiveness of glucocorticoid treatment. Takemori N; Kondo K; Kawamura T; Imai K; Sakurai H; Sato T Am J Hematol; 2001 Jan; 66(1):62-3. PubMed ID: 11426497 [TBL] [Abstract][Full Text] [Related]
15. [Treatment of multiple myeloma in stages I and II. Comparative study of an M-2 protocol and melphalan-prednisone]. Montalbán C; Zapatero A; Blanco L; Sevilla F; García Laraña J; Odriozola J Sangre (Barc); 1984; 29(6):993-9. PubMed ID: 6549486 [No Abstract] [Full Text] [Related]
16. Multiple myeloma: the National University Hospital (NUH) experience. Lim HL; Teo CP; Wong K; Kuperan P; Suri R; Tan YO; Kueh YK Singapore Med J; 1994 Aug; 35(4):371-3. PubMed ID: 7899894 [TBL] [Abstract][Full Text] [Related]
17. [The influence of verapamil on platelet function in patients with multiple myeloma]. Sokołowska B; Dmoszyńska A; Walter-Croneck A; Wojtaszko M Pol Merkur Lekarski; 1997 Feb; 2(8):109-10. PubMed ID: 9538652 [TBL] [Abstract][Full Text] [Related]
18. [Evaluation of the prognosis and response to therapy in multiple myeloma]. Venturino M; Geniram A; Guarino P; Scio P; Marini U Recenti Prog Med; 1984 May; 75(5):451-61. PubMed ID: 6484288 [No Abstract] [Full Text] [Related]
19. [Clinical trial of a combination of human lymphoblastoid interferon (HLBI), melphalan and prednisolone (HLBI-MP) in multiple myeloma]. Hara M; Nakamura T; Fujii Y Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1338-41. PubMed ID: 3579331 [TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy with MCNU, vindesine, melphalan, and prednisolone (MCNU-VMP therapy) in induction therapy for multiple myeloma. Japan Myeloma Study Group. Imamura Y; Takagi T; Yawata Y; Nishinarita S; Kosaka M; Mikuni C; Takatsuki K; Sezaki T; Mori M; Tsuchiya J Int J Hematol; 1994 Feb; 59(2):113-23. PubMed ID: 8018904 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]